Summary Hepatocyte growth factor (HGF) has been known as a multiple function factor, which also stimulates early haematopoiesis. In this study, we found that HGF was expressed at both the RNA and protein levels in acute myeloid leukaemia (AML) and chronic myeloid leukaemia (CML). In patients with AML (n = 20) and CML (n = 5), bone marrow plasma HGF concentrations were 20.44 ± 6.26 (mean ± s.e.) ng ml' and 7.17 ± 0.53 ng ml-' respectively. These were significantly higher (P< 0.01) than the value for normal subjects (n = 26): mean 0.92 ± 0.09 ng ml-'. Constitutive HGF production was observed in freshly prepared leukaemic blast cells from three patients with high HGF levels of bone marrow plasma. Expression of HGF mRNA was correlated with bone marrow plasma HGF levels. After complete remission was obtained in six patients, bone marrow plasma HGF levels were significantly decreased. In contrast, the HGF mRNA was less abundantly expressed in acute lymphoid leukaemia (ALL). In patients with ALL (n = 5), bone marrow plasma HGF concentration (0.69 ± 0.14 ng ml -) remained low within the value for normal subjects. These results suggest that some populations of myeloid lineage cells have the ability to produce HGF.
Hepatocyte growth factor (HGF), also known as a scatter factor (Weidner et al., 1990) , was initially identified as a mitogen for primary cultured adult rat hepatocytes, from rat platelets (Russell et al., 1984) and from the plasma of patients with fulminant hepatic failure (Gohda et al., 1986) . It was purified from rat platelets as a disulphide-linked heterodimeric molecule composed of a 69 kDa a-chain and a 34 kDa ,3-chain (Nakamura et al., 1986, 1987) . Molecular cloning of HGF cDNA revealed that both chains of HGF are encoded in a single gene (Miyazawa et al., 1989; Nakamura et al., 1989; Seki et al., 1990; Tashiro et al., 1990) . Accumulating evidence indicates that, in addition to its effect on hepatocytes, HGF is a unique multifunctional cytokine acting on a wide variety of cells as a mitogen (Igawa et al., 1991; Kan et al., 1991; Rubin et al., 1991) , a motogen (Gherardi et al., 1989; Gherardi and Stoker, 1991) , a morphogen (Montesano et al., 1991) , an angiogenetic factor (Bussolino et al., 1992; Grant et al., 1993) and a tumour cytotoxic factor (Higashio et al., 1990); Tajima et al., 1991) . Indeed, HGF mRNA is expressed in various tissues, including kidney Nagaike et al., 1991) , heart , lung Yanagita et al., 1992 Yanagita et al., , 1993 ) and brain , as well as in injured liver (Kinoshita et al., 1989) .
Previous reports have shown that HGF stimulates growth of haematopoietic progenitor cells derived from mouse (Kmiecik et al., 1992; Nishino et al., 1995) and human (Galimi et al., 1994) . Of particular interest is HGF receptor (HGFR)/c-met mRNA expression Naldini et al., 1991a,b; Giordano et al., 1993) has been reported in several murine haematopoietic progenitor cell lines (Kmiecik et al., 1992; Mizuno et al., 1993) and human haematopoietic progenitor cells (Galimi et al., 1994) . Recently, we reported that the human promyelocytic leukaemia cell line, HL-60, produces HGF (Nishino et al., 1991; Inaba et al., 1993) . More recently, Nakamura et al. (1994a) reported that a high level of HGF was detected in blood and bone marrow plasma of leukaemia patients. These data strongly suggest the possibility that HGF may play an important role in haematopoiesis and that it may act as an autocrine or paracrine growth factor in the development of leukaemia.
In this study, we determined HGF production and its gene expression in leukaemic blast cells from myeloid leukaemic patients and the drastic diminution of HGF levels in bone marrow plasma by inducing remission.
Materials and methods

Patients
Thirty patients with leukaemia were studied. Mean age was 49.1 years, with a range from 21 to 75. The diagnosis was based on cell morphology and genetic markers. The clinical data for the patients are shown in Table I . The subtypes and numbers of cases were: 20 cases of acute myeloid leukaemia (AML) [Ml (n = 3), M2 (n = 4), M3 (n = 4), M4 (n = 3), 20.44 ± 6.26 ng ml-' (range from 0.56 to 102.6 ng ml') and 7.17 ± 0.53 ng ml-' (range from 5.68 to 8.58 ng ml-') respectively. These values were both significantly greater than that for normal subjects (P<0.01). HGF concentrations in patients with ALL (n = 5) and IDA (n = 4) were 0.69 ± 0.14 ng ml-' (range from 0.20 to 1.01 ng ml-') and 0.90 ± 0.29 ng ml-' (range from 0.58 to 1.76 ng ml-') respectively. HGF levels were significantly lower in peripheral blood than those in bond marrow plasma, as reflected by the comparison of HGF levels in both specimens obtained at the same time in nine cases (data not shown).
Northern blot analysis
To confirm the possibility of HGF production in leukaemic blast cells from AML and CML patients, Northern blot analysis of total cellular RNA from leukaemic blast cells using a human HGF cDNA as a probe was performed. Figure 2 shows a single band of 6.0 kb HGF transcript in patients with AML and CML. Supporting the specificity of HGF production for the cells in the myeloid lineage, very low expression of the HGF transcript was obtained from ALL patients. with AML, morphologically complete remission was obtained after chemotherapy. Figure 4 shows a comparison of bone marrow HGF levels between the leukaemic and the remission state. Bone marrow HGF levels were significantly decreased in the remission state.
Discussion
In the present study, we have shown that HGF levels in bone marrow plasma from AML and CML patients were significantly higher than those for normal subjects. These Mizuno et al., 1993) . Therefore, HGF may also play a role as an autocrine growth factor in leukaemic blast cells. To explore this possibility, we have investigated the expression of the HGFR/c-met gene in cases (M03, M09, M1O, M11, M12, M13 as AML and CMO1 as CML), poly A RNAs of bone marrow blast cells from patients with AML and CML were analysed. However, HGFR/c-met-specific mRNA was not detected in any case (data not shown). Furthermore, recombinant human HGF had no effect on proliferation of blast cells from patients with AML (data not shown). Jucker et al. (1994) have reported that HGFR/c-met mRNA is overexpressed in some cases of leukaemia and lymphoma. Since they have demonstrated that expression of the HGFR/c-met gene is detected in only I AML case out of 29 leukaemias, HGF still might be an autocrine growth factor in a few cases of AML. Kmiecik et al. (1992) have reported that HGFR/c-met mRNA and protein are expressed in the progenitor-enriched murine bone marrow cells and that HGF has a synergistic effect with interleukin 3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) to stimulate colony formation of bone marrow cells. Galimi et al. (1994) have reported that HGFR/c-met is expressed in human CD34-positive haematopoietic progenitor cells and that HGF stimulates erythroid and multipotent progenitor cells in the presence of cytokines such as erythropoietin, IL-3 and GM-CSF. During embryonic development, haematopoiesis originates in the yolk sac, then moves to the liver and spleen and finally settles in the bone marrow. Of interest, HGF and/or HGFR/c-met are expressed in the fetal liver (Selden et al., 1990; Hu et al., 1993; Galimi et al., 1994) and yolk sac (Chan et al., 1988) . Recently, Nishino et al. (1995) have reported that both HGF and HGFR/c-met mRNA are expressed in the mouse fetal liver in the middle and late stages when haematopoiesis is most active. These results suggest that HGF may be a modulator in early haematopoietic processes. Our findings and the findings of others indicating HGF production by some populations of myeloid lineage ,cells, HGF may have positive-feedback effects on the growth of haematopoietic progenitors.
